Deutsche Bank AG Invests $7.23 Million in BioMarin Pharmaceutical Inc. $BMRN

Deutsche Bank AG acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, HoldingsChannel reports. The fund acquired 126,286 shares of the biotechnology company’s stock, valued at approximately $7,226,000.

Several other hedge funds and other institutional investors have also made changes to their positions in BMRN. Rice Hall James & Associates LLC bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $14,203,000. Swedbank AB lifted its stake in BioMarin Pharmaceutical by 70.6% in the 4th quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock valued at $47,350,000 after purchasing an additional 329,794 shares during the last quarter. LSV Asset Management grew its holdings in BioMarin Pharmaceutical by 4.3% during the fourth quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock worth $52,429,000 after purchasing an additional 36,700 shares during the period. GSA Capital Partners LLP bought a new position in BioMarin Pharmaceutical during the second quarter worth about $944,000. Finally, C WorldWide Group Holding A S increased its position in BioMarin Pharmaceutical by 12.6% during the fourth quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company’s stock worth $15,918,000 after buying an additional 30,000 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BMRN has been the topic of several research analyst reports. Piper Sandler upped their price objective on BioMarin Pharmaceutical from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Weiss Ratings downgraded BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. Citigroup boosted their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. UBS Group restated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Finally, Royal Bank Of Canada cut their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $88.83.

BioMarin Pharmaceutical Stock Down 2.4%

BioMarin Pharmaceutical stock opened at $65.07 on Tuesday. The stock has a market cap of $12.60 billion, a P/E ratio of 175.86, a P/E/G ratio of 0.48 and a beta of 0.24. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The company’s 50-day moving average price is $60.85 and its two-hundred day moving average price is $57.93.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the previous year, the company posted $1.44 earnings per share. The business’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, analysts expect that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.